CLK1 Activators
The chemical class termed CLK1 Activators encompasses a range of compounds that, while not directly activating CLK1, have the potential to influence its activity through indirect mechanisms. These compounds interact with various cellular signaling pathways and processes, particularly those related to splicing regulation and kinase activity, thereby affecting CLK1 function.
Key compounds in this class, such as TG003 and SRPIN340, are known for their inhibitory effects on CLK1 and related kinases. The inhibition exerted by these compounds can lead to changes in the cellular environment that may result in compensatory mechanisms activating CLK1. For example, the inhibition of CLK1 by TG003 could lead to altered spliceosome activity, prompting the cell to adjust the regulation of splicing factors, indirectly influencing CLK1 activity. Similarly, SRPIN340's inhibition of SR protein kinases can change the phosphorylation states of splicing regulators, indirectly affecting CLK1's role in this process. Other compounds like Chlorhexidine, Indirubin-3'-monoxime, and Harmine affect a broader range of cellular processes but can still indirectly influence CLK1 activity. These compounds interact with various kinases and signaling pathways, potentially leading to changes in the phosphorylation state and activity of proteins involved in splicing, where CLK1 plays a crucial role
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $79.00 $321.00 $671.00 | 1 | |
This compound is a known inhibitor of various kinases, including CDKs and GSK-3β. Its broad kinase inhibition profile can indirectly influence CLK1 activity in cellular signaling. | ||||||
Kenpaullone | 142273-20-9 | sc-200643 sc-200643A sc-200643B sc-200643C | 1 mg 5 mg 10 mg 25 mg | $61.00 $153.00 $231.00 $505.00 | 1 | |
Kenpaullone is an inhibitor of GSK-3β and CDKs. By modulating these kinases, it can indirectly affect CLK1's role in splicing regulation. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $72.00 $297.00 | 4 | |
As a CDK inhibitor, Purvalanol A can indirectly affect cellular processes regulated by CLK1, particularly in splicing and cell cycle regulation. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine is a CDK inhibitor that can indirectly influence CLK1 activity through its effects on cell cycle regulators and splicing factors. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
DRB is a transcription inhibitor that can indirectly affect CLK1 by altering the transcription of genes involved in splicing and CLK1 regulation. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol is a broad-spectrum CDK inhibitor. Its action on CDKs can indirectly impact CLK1's activity in splicing regulation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor. Its modulation of the PI3K/Akt pathway can indirectly affect CLK1's role in cellular signaling and splicing. | ||||||
K-252a | 99533-80-9 | sc-200517 sc-200517B sc-200517A | 100 µg 500 µg 1 mg | $129.00 $214.00 $498.00 | 19 | |
K252a is a kinase inhibitor with broad specificity, including inhibition of protein kinase C. This can indirectly influence CLK1's activity in splicing regulation. | ||||||